ArticleJournal of psoriasis and psoriatic arthritis2022
Practice Patterns of Palmoplantar Pustulosis: Patient Demographics and Treatment Options.
Article in Journal of psoriasis and psoriatic arthritis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Palmoplantar pustulosis (PPP) is a chronic skin condition characterized by sterile pustules on the palms and soles. This condition is more commonly reported among women and smokers causing considerable discomfort and interference with daily activities. Although there are various off-label treatment options available for PPP, there remains a demand to identify more effective and safer treatments. Objective: To review the patient demographics and treatment patterns of our PPP patient population. Methods: A retrospective chart review was performed at a dermatology office with two locations in Ontario, Canada. Results: We identified 71 adult PPP patients. A third of patients did not return for follow up after diagnosis. Among those who returned for follow-up, 20% were managed with topical therapy alone. Of our patients who took systemic treatment for PPP, apremilast, followed by ustekinumab and guselkumab, had the greatest retention of therapy. Conclusion: Targeting PDE4, IL-12/23 and IL-23 provided some benefit for our patients with PPP leading to greatest retention of therapy over time. Further investigation is required into the cause for high no-show rates and the search for effective and safe treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.